Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...
Drug
Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...
Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...
Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study
Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...
BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....
Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study
China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...
Zhejiang Suspends Generic Nesina Trading Due to IP Disputes
Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the...
Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...
CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease
The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...
CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...
Kelun Pharma’s Generic Jardiance Gains New Indication in China
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...
NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis
The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...